C. Calvet

776 total citations
18 papers, 528 citations indexed

About

C. Calvet is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Biotechnology. According to data from OpenAlex, C. Calvet has authored 18 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Biotechnology. Recurrent topics in C. Calvet's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Microbial Inactivation Methods (4 papers). C. Calvet is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Microbial Inactivation Methods (4 papers). C. Calvet collaborates with scholars based in France, United States and United Kingdom. C. Calvet's co-authors include Lluis M. Mir, Franck M. André, Richard Morgan, Marc Demeter, Huimin Kong, R. Corre, François-Emery Cotté, Matteo Giaj Levra, C. Chouaïd and Jean‐Baptiste Assié and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

C. Calvet

16 papers receiving 523 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Calvet France 8 230 184 173 149 121 18 528
Tanja Jesenko Slovenia 12 183 0.8× 126 0.7× 92 0.5× 137 0.9× 86 0.7× 35 381
P. Urbas United States 9 386 1.7× 267 1.5× 225 1.3× 319 2.1× 308 2.5× 12 814
Joshua W. Henshaw United States 10 124 0.5× 390 2.1× 121 0.7× 306 2.1× 50 0.4× 15 580
A Godál Norway 15 187 0.8× 86 0.5× 84 0.5× 178 1.2× 307 2.5× 28 526
Reintgen Ds United States 8 328 1.4× 166 0.9× 227 1.3× 103 0.7× 149 1.2× 9 526
Lien Vandenberk Belgium 6 56 0.2× 315 1.7× 125 0.7× 170 1.1× 425 3.5× 7 682
Ilya Sedliarou Japan 8 74 0.3× 127 0.7× 116 0.7× 289 1.9× 25 0.2× 10 562
Xiangyi Shi China 10 50 0.2× 70 0.4× 44 0.3× 164 1.1× 156 1.3× 15 407
Sara Collins United States 9 99 0.4× 65 0.4× 64 0.4× 160 1.1× 36 0.3× 19 290
Carlotta Petti Australia 6 46 0.2× 131 0.7× 77 0.4× 334 2.2× 37 0.3× 6 467

Countries citing papers authored by C. Calvet

Since Specialization
Citations

This map shows the geographic impact of C. Calvet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Calvet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Calvet more than expected).

Fields of papers citing papers by C. Calvet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Calvet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Calvet. The network helps show where C. Calvet may publish in the future.

Co-authorship network of co-authors of C. Calvet

This figure shows the co-authorship network connecting the top 25 collaborators of C. Calvet. A scholar is included among the top collaborators of C. Calvet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Calvet. C. Calvet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wolf, Jürgen, Sarah Goring, Adam Lee, et al.. (2025). Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC. Cancers. 17(5). 748–748.
2.
3.
4.
Assié, Jean‐Baptiste, R. Corre, Matteo Giaj Levra, et al.. (2020). Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Therapeutic Advances in Medical Oncology. 12. 3863582277–3863582277. 17 indexed citations
5.
Levra, Matteo Giaj, François-Emery Cotté, R. Corre, et al.. (2019). MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S274–S275. 2 indexed citations
6.
Assié, Jean‐Baptiste, François-Emery Cotté, Matteo Giaj Levra, et al.. (2019). P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S708–S708. 1 indexed citations
7.
Levra, Matteo Giaj, François-Emery Cotté, R. Corre, et al.. (2019). Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 140. 99–106. 88 indexed citations
8.
Barlési, Fabrice, A. Dixmier, D. Debieuvre, et al.. (2019). Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study. Annals of Oncology. 30. v613–v613. 1 indexed citations
9.
Pérol, M., A. Dixmier, Fabrice Barlési, et al.. (2019). Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study. Annals of Oncology. 30. ii48–ii48. 3 indexed citations
10.
Asselain, Bernard, Fabrice Barlési, D. Debieuvre, et al.. (2019). IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany. Annals of Oncology. 30. v614–v614. 2 indexed citations
11.
Chouaïd, C., Matteo Giaj Levra, R. Corre, et al.. (2019). Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study). Annals of Oncology. 30. v521–v521. 1 indexed citations
12.
Calvet, C. & Lluis M. Mir. (2016). The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer and Metastasis Reviews. 35(2). 165–177. 89 indexed citations
13.
Calvet, C., Jessie Thalmensi, Christelle Liard, et al.. (2014). Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice. Molecular Therapy — Methods & Clinical Development. 1. 14045–14045. 21 indexed citations
14.
Calvet, C., et al.. (2014). Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology. 3(4). e28131–e28131. 150 indexed citations
15.
Calvet, C., Franck M. André, & Lluis M. Mir. (2014). The Culture of Cancer Cell Lines as Tumorspheres Does Not Systematically Result in Cancer Stem Cell Enrichment. PLoS ONE. 9(2). e89644–e89644. 58 indexed citations
16.
Calvet, C., Franck M. André, & Lluis M. Mir. (2014). Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo. OncoImmunology. 3(4). e28540–e28540. 24 indexed citations
17.
Morgan, Richard, et al.. (2000). Characterization of the Specific DNA Nicking Activity of Restriction Endonuclease N.BstNBI. Biological Chemistry. 381(11). 1123–1125. 68 indexed citations
18.
Guinnepain, M.T., D Herman, B. David, et al.. (1983). Allergie aux acariens (Dermatophagoides pteronyssinus) et métérologie. Revue Française d Allergologie et d Immunologie Clinique. 23(4). 193–197. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tanja Jesenko Breakdown of academic impact, for papers by P. Urbas Breakdown of academic impact, for papers by Joshua W. Henshaw Breakdown of academic impact, for papers by A Godál Breakdown of academic impact, for papers by Reintgen Ds Breakdown of academic impact, for papers by Lien Vandenberk Breakdown of academic impact, for papers by Ilya Sedliarou Breakdown of academic impact, for papers by Xiangyi Shi Breakdown of academic impact, for papers by Sara Collins Breakdown of academic impact, for papers by Carlotta Petti
Rankless by CCL
2026